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detection of N. gonorrhoeae in a country with a low
prevalence, such as Peru. The negative results for
97% of the patients provided a high negative
predictive value of 100%, which is an important
parameter for a test to be used in settings with a
low prevalence.
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ABSTRACT
Neisseria meningitidis W-135 accounted for nine
(1.6%) of 562 cases of invasive meningococcal
disease and 17 (3.9%) of 430 meningococcal
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isolates from healthy carriers. There was no
mortality associated with the invasive nine iso-
lates, which belonged to subtype P1.6 and geno-
subtype P1.18-1. All invasive isolates and 15 of the
17 isolates from healthy carriers belonged to
sequence type 22 by multilocus sequence typing,
and showed a similarity of > 85% by pulsed-field
gel electrophoresis following digestion with NheI.
These results demonstrate that W-135 isolates in
the Basque region of northern Spain have a high
degree of similarity and are almost clonal.
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In developed countries, Neisseria meningitidis
serogroup W-135 normally accounts for only a
small number of cases of meningococcal disease.
After the 2000 and 2001 Hajj pilgrimages to Saudi
Arabia, a worldwide outbreak of W-135
(W-135:2a:P1.5,2) meningococcal disease was
reported [1–3]. This outbreak, with cases reported
in nine European countries, generated consider-
able interest in the epidemiology of this men-
ingococcal serogroup. The aim of the present
study was to investigate the incidence of men-
ingococcal disease and the prevalence of the
W-135 meningococcus among carriers in northern
Spain during the last 15 years, as well as the
phenotypic and genotypic characteristics of these
isolates.
All 330 invasive isolates of meningococci
obtained in Gipuzkoa during 1990–2004, and all
isolates from 430 healthy carriers of meningococci
during the same period, were included in the
study. Gipuzkoa is a province of the Basque
Country, situated in the north of Spain near the
border with France. The region has a population
of 611 027, of which 81 945 are aged < 14 years.
An additional 232 invasive isolates obtained from
other provinces of the Basque Country during
1998–2004 were also included in the study.
Serotyping and sero-subtyping were performed
by ELISA as described previously [4], with mono-
clonal antibodies (Rijjksinstituut voor Volksgez-
ondheid, Bilthoven, The Netherlands) specific for
six serotypes and 13 sero-subtypes.
Genomic DNA was extracted with a QIAamp
DNA Blood Mini kit (Qiagen, Hilden, Germany).
Geno-subtypes were determined as described
previously [5] by amplification of two fragments
of the porA gene coding for VR1 and VR2,
followed by sequencing and comparison of the
deduced amino-acid sequence with the N. menin-
gitidis PorA variable region database (http://
neisseria.org/nm/typing/pora/).
Multilocus sequence typing (MLST) was per-
formed by amplification and sequencing of seven
housekeeping genes [6]. Primers, determination
of sequence alleles and designation of sequence
types were as described on the MLST website
(http://neisseria.org/nm/typing/mLst/).
For pulsed-field gel electrophoresis (PFGE),
DNA was extracted from a bacterial suspension
adjusted to an OD560 of 0.65 following incubation
with lysozyme and proteinase K. DNA was
digested with NheI (Amersham Pharmacia Bio-
tech, Little Chalfont, UK) and separated by
electrophoresis in agarose 1% w ⁄v gels. PFGE
patterns were analysed with Diversity Database
fingerprinting software v.2 (Bio-Rad, Hercules,
CA, USA) and a dendogram was constructed by
the unweighted pair-group method with arith-
metic averages, using the Dice coefficient and a
position tolerance of 1%. Isolates with > 85%
similarity were considered to represent a clone
[7].
Of the 562 meningococcal isolates from the
blood or cerebrospinal fluid of 562 individuals
with invasive meningococcal disease, nine (1.6%)
belonged to serogroup W-135; of these, five
(1.5%) were among the 330 isolates from Gipuz-
koa. Six of the nine infections occurred in infants
and children (aged 4 months, 7 months,
8 months, 2 years, 9 years and 11 years), and the
three remaining infections occurred in adults
(aged 29, 60 and 82 years). No epidemiological
relationship was identified among the patients
with W-135 meningococcal disease. Meningococci
were isolated from cerebrospinal fluid of two
patients and from blood of the remaining seven
patients. None of the patients died from W-135
meningococcal infection during this period.
Table 1 shows the phenotypic and genotypic
characteristics of the nine W-135 isolates. PFGE
following digestion with NheI showed three PFGE
patterns for the invasive isolates with a similarity
of > 85% (Fig. 1), which were therefore consid-
ered to represent a single clone.
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Of the 430 meningococcal isolates from the
pharynges of healthy carriers, 17 (3.9%) belonged
to serogroup W-135. Fifteen (88.2%) isolates from
carriers had the same subtype and sequence type
as the invasive isolates, and their PFGE patterns
showed a similarity of > 85%with the major clone
(Fig. 1). The two discrepant isolates belonged to
ST-254 and ST-1768, and their PFGE patterns
showed no similarity between each other or with
the major clone.
The results indicate that serogroup W-135 is a
minor serogroup in this region of Spain, as in other
countries of western Europe, where it has been




2031%20March04.pdf). None of the isolates in the
present study belonged to the W-135:2a:P1.5,2 ET-
37 clonal complex, which is the W-135 type ⁄ sub-
type isolated most frequently in previous studies.
To date, only one W-135 isolate of this clonal
complex has been isolated in Spain (http://
www.pubmlst.org/neisseria/) and, to our know-
ledge, this isolate was not related to Hajj pilgrims
or their contacts. The phenotypic and genotypic
(MLST and PFGE) analyses indicated a close
relationship between the invasive isolates and
those from healthy carriers.
Isolates belonging to the ST-22 complex, similar
to those from the Basque Country, have also been
isolated in other regions of Spain (http://
www.pubmlst.org/neisseria/), as well as in other
European [8–11] and non-European countries [9].
The ST-22 complex represents the second most
frequent clonal complex found among serogroup
W-135 isolates after the ET-37 complex. Com-
pared with the low diversity of isolates found in
the Basque Country, other studies have reported
greater phenotypic and genotypic diversity
among sporadic meningococcal W-135 isolates,
with coexistence of isolates from distinct clonal
complexes, and high genetic polymorphism [8,9].
The rate of immigration to the Basque Country is
lower than that to other regions of Spain, and
only 1.4% of inhabitants originate from countries
outside Spain (http://www.eustat.es/), which
reduces the opportunities for importation of
strains. Otherwise, the low circulation and diver-
sity of W-135 serogroup isolates in this region
might facilitate the dissemination of other, dis-
tinct, W-135 strains, with the potential to cause an
epidemic [12] in a population with low immunity
against such strains. In addition, the natural
ability of the meningococcus to undergo genetic
transformation could be stimulated by the select-
ive immune pressure generated by monovalent
vaccines against meningococci [8,13,14]. The US
Food and Drug Administration has recently
licensed a tetravalent (serogroups A, C, Y and
W-135) conjugate meningococcal vaccine, and
other similar vaccines may soon be made avail-
able. The substitution of this tetravalent conjugate
vaccine for the current serogroup C monovalent
vaccine in Europe will be influenced by the
incidence and prevalence of the minor sero-
Table 1. Phenotypic and genotypic characteristics of nine










January 1993 NT:P1.6 P1.18-1,3 22 ST-22 complex
June 2000 NT:P1.6 P1.18–1, 25 22 ST-22 complex
July 1994 NT:P1.6 P1.18-1,3 22 ST-22 complex
January 1998 NT:P1.6 P1.18-1,3 22 ST-22 complex
February 1997 NT:P1.6 P1.18-1,3 22 ST-22 complex
May 2004 NT:P1.6 P1.18-1,3 22 ST-22 complex
November 1993 4:P1.6 P1.18-1,3 22 ST-22 complex
April 1998 NT:P1.6 P1.18-1,3 22 ST-22 complex
February 1997 4:P1.6 P1.18-1,3 22 ST-22 complex
MLST, multilocus sequencing typing.
1 1098765432 11 12 13
Fig. 1. Pulsed-field gel electrophoresis of six invasive
isolates of Neisseria meningitidis W-135 (lanes 2–7) and six
from healthy carriers (lanes 8–13) after digestion with NheI.
Lane 1, molecular size marker.
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groups (A, W-135 and Y), and the importance
given to the risk of capsular switching. As a first
step, the epidemiology of these minority sero-
groups in the various regions of Europe should
be studied in greater detail.
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ABSTRACT
This study examined the ability of PCR to amplify
Leishmania DNA, stored on Giemsa-stained slides,
from American cutaneous leishmaniasis (ACL)
patients. In total, 475 slides stored for up to
36 years were obtained from an outpatient clinic
in a Brazilian ACL-endemic region, and Leish-
mania DNA was amplified from 395 (83.2%) of the
DNA samples using primers specific for the
minicircle kinetoplast DNA. Restriction fragment
length polymorphism analysis of these amplicons
demonstrated that Leishmania (Viannia) braziliensis
was the only species present in these samples. The
results demonstrated that archived Giemsa-
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